Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing
| Autor: | Peter L. Molloy, Glenn S. Brown, Snigdha Gaur, Graeme P. Young, Susanne K. Pedersen, Robert Dunne, David Wattchow, Letitia Pimlott, Lawrence C. LaPointe, Melissa L. Thomas, Aidan McEvoy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Adenoma
Oncology medicine.medical_specialty Biomarker validation Hyaluronoglucosaminidase Library science lcsh:Medicine Gastroenterology and Hepatology Biology Diagnostic Medicine Internal medicine Biomarkers Tumor Pathology Cancer Detection and Diagnosis medicine Humans Blood testing lcsh:Science Oligonucleotide Array Sequence Analysis Clinical genomics Multidisciplinary lcsh:R Industrial research Proteins Cancers and Neoplasms Molecular biomarkers Colorectal cancer Gene Expression Regulation Neoplastic Medicine lcsh:Q Colorectal Neoplasms Research Article General Pathology |
| Zdroj: | PLoS ONE, Vol 7, Iss 1, p e29059 (2012) PLoS ONE |
| ISSN: | 2381-3652 |
| Popis: | Results: Genome-wide analysis uncovered reproducible gene expression signatures for both adenomas and cancers compared to controls. 386/489 (79%) of the adenoma and 439/529 (83%) of the adenocarcinoma biomarkers were validated in independent tissues. We also identified genes differentially expressed in adenomas compared to cancer. KIAA1199 was selected for further analysis based on consistent up-regulation in neoplasia, previous studies and its interest as an uncharacterized gene. Plasma KIAA1199 RNA levels were significantly higher in patients with either cancer or adenoma (31/ 40) compared to neoplasia-free controls (6/20). This work was co-funded by Flinders University of South Australia and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) of Australia. Drs. Dunne, Molloy and Brown are employed by CSIRO. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding was also provided by Clinical Genomics Pty Ltd., a company involved in the discovery and commercialization of biomarkers for colorectal cancer. Drs. LaPointe, Pedersen, Gaur, McEvoy and Thomas are employed by Clinical Genomics Pty Ltd and Prof. Young is a paid consultant of Clinical Genomics Pty Ltd. The funder thus played roles in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Mrs. Pimlott and Dr. Wattchow have nothing to disclose. This work was co-funded by Clinical Genomics Pty Ltd, a company involved in the discovery and commercialization of biomarkers for colorectal cancer. Drs. LaPointe, Pedersen, Gaur, McEvoy and Thomas are employed by Clinical Genomics Pty Ltd. Prof. Young is a paid consultant of Clinical Genomics Pty Ltd. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|